Trials / Completed
CompletedNCT00198510
Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage
Phase III Safety and Efficacy Study of Vitrase (Ovine Hyaluronidase) for Ophthalmic Intravitreal Injection for Clearance of Severe Vitreous Hemorrhage
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 750 (planned)
- Sponsor
- Bausch & Lomb Incorporated · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if intravitreal injection of Vitrase (ovine hyaluronidase) clears vitreous hemorrhage
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vitrase | 7.5 IU of Vitrase |
| DRUG | Vitrase | 55 IU of Vitrase |
| DRUG | Vitrase | 75 IU of Vitrase |
Timeline
- Start date
- 1998-11-01
- Primary completion
- 2001-09-01
- Completion
- 2003-03-01
- First posted
- 2005-09-20
- Last updated
- 2013-03-15
Locations
73 sites across 3 countries: United States, Canada, Mexico
Source: ClinicalTrials.gov record NCT00198510. Inclusion in this directory is not an endorsement.